Search

Displaying results 3681 - 3690 of 4359 in total
  1. Drug

    ZYC300

    go.drugbank.com/drugs/DB04986
    Investigational

    It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.

  2. Drug

    Tanespimycin

    go.drugbank.com/drugs/DB05134
    Investigational

    Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90).

  3. Drug

    D-threo-neopterin

    go.drugbank.com/drugs/DB02385
    Experimental

    (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin.

  4. Drug

    Isaralgagene civaparvovec

    go.drugbank.com/drugs/DB16808
    Investigational

    Isaralgagene civaparvovec, formerly known as ST-920, is liver-tropic rAAV 2/6 vector carrying the cDNA for human alpha-galactosidase A (α-Gal A) enzyme.

  5. Drug

    Difloxacin

    go.drugbank.com/drugs/DB11511
    ExperimentalVet approved

    As an antibacterial, it presents a broad bactericidal spectrum and its effects are dependent on its concentration.

  6. Drug

    TPMPA

    go.drugbank.com/drugs/DB16754
    Experimental

    [A245308,A245313] TPMPA is used as a pharmacological probe for the investigation of GABA<sub>C</sub> receptor function.[A245313] … TPMPA ((1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid) is a selective antagonist of GABA<sub>C</sub> receptors (also known as GABA-ρ or GABA<sub>A-ρ</sub> receptors).

  7. Drug

    Pranlukast

    go.drugbank.com/drugs/DB01411
    Investigational

    Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

  8. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    However, studies revealed that NSF was associated with linear GBCAs, not macrocyclic GBCAs, such as gadopiclenol.

  9. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065]

  10. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR).